PSA-velocity bei prostataerkrankungen

Translated title of the contribution: PSA velocity in diseases of the prostate

R. Thiel, J. D. Pearson, H Ballentine Carter

Research output: Contribution to journalArticle

Abstract

Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

Original languageGerman
Pages (from-to)19-23
Number of pages5
JournalAktuelle Urologie
Volume29
Issue number1
StatePublished - Feb 1998

Fingerprint

Prostate
Prostatic Neoplasms
Prostatic Hyperplasia
Prostatectomy
Recurrence

Keywords

  • Prostate specific antigen
  • Review
  • Velocity

ASJC Scopus subject areas

  • Nephrology

Cite this

Thiel, R., Pearson, J. D., & Carter, H. B. (1998). PSA-velocity bei prostataerkrankungen. Aktuelle Urologie, 29(1), 19-23.

PSA-velocity bei prostataerkrankungen. / Thiel, R.; Pearson, J. D.; Carter, H Ballentine.

In: Aktuelle Urologie, Vol. 29, No. 1, 02.1998, p. 19-23.

Research output: Contribution to journalArticle

Thiel, R, Pearson, JD & Carter, HB 1998, 'PSA-velocity bei prostataerkrankungen', Aktuelle Urologie, vol. 29, no. 1, pp. 19-23.
Thiel R, Pearson JD, Carter HB. PSA-velocity bei prostataerkrankungen. Aktuelle Urologie. 1998 Feb;29(1):19-23.
Thiel, R. ; Pearson, J. D. ; Carter, H Ballentine. / PSA-velocity bei prostataerkrankungen. In: Aktuelle Urologie. 1998 ; Vol. 29, No. 1. pp. 19-23.
@article{fa3c0e3fc9cf41ac9fd637d274481107,
title = "PSA-velocity bei prostataerkrankungen",
abstract = "Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70{\%} and specificity among men without prostate cancer was 95{\%}. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.",
keywords = "Prostate specific antigen, Review, Velocity",
author = "R. Thiel and Pearson, {J. D.} and Carter, {H Ballentine}",
year = "1998",
month = "2",
language = "German",
volume = "29",
pages = "19--23",
journal = "Aktuelle Urologie",
issn = "0001-7868",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - PSA-velocity bei prostataerkrankungen

AU - Thiel, R.

AU - Pearson, J. D.

AU - Carter, H Ballentine

PY - 1998/2

Y1 - 1998/2

N2 - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

AB - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.

KW - Prostate specific antigen

KW - Review

KW - Velocity

UR - http://www.scopus.com/inward/record.url?scp=0032361313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032361313&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032361313

VL - 29

SP - 19

EP - 23

JO - Aktuelle Urologie

JF - Aktuelle Urologie

SN - 0001-7868

IS - 1

ER -